299 related articles for article (PubMed ID: 32593644)
1. Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification?
Franzese C; Badalamenti M; Comito T; Franceschini D; Clerici E; Navarria P; Loi M; D'agostino G; Baldaccini D; Chiola I; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
Radiother Oncol; 2020 Sep; 150():184-190. PubMed ID: 32593644
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic Body Radiotherapy for Lymph-Nodal Oligometastatic Prostate Cancer: A Multicenter Retrospective Experience.
Cuccia F; Tamburo M; Piras A; Mortellaro G; Iudica A; Daidone A; Federico M; Zagardo V; Ferini G; Marletta F; Spatola C; Fazio I; Filosto S; Pergolizzi S; Ferrera G
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629732
[No Abstract] [Full Text] [Related]
3. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiation therapy for the treatment of lymph node metastases: a retrospective mono-institutional study in a large cohort of patients.
Caivano D; Bonome P; Pezzulla D; Rotondi M; Sigillo RC; De Sanctis V; Valeriani M; Osti MF
Front Oncol; 2023; 13():1163213. PubMed ID: 37601675
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
[TBL] [Abstract][Full Text] [Related]
6. Total tumor volume as a predictor of survival in patients with multiple oligometastases treated with stereotactic ablative radiotherapy (SABR).
Franzese C; Vernier V; Franceschini D; Comito T; Navarria P; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Marini B; Galdieri C; Mancosu P; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10495-10503. PubMed ID: 37280407
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases.
Franzese C; Comito T; Tripoli A; Franceschini D; Clerici E; Navarria P; Badalamenti M; D'agostino G; Loi M; Mancosu P; Reggiori G; Tomatis S; Scorsetti M
Clin Exp Metastasis; 2020 Oct; 37(5):565-573. PubMed ID: 32556682
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting local control of pulmonary oligometastases treated with stereotactic body radiotherapy.
Sharma A; Duijm M; Oomen-de Hoop E; Aerts JG; Verhoef C; Hoogeman M; Nuyttens JJ
Acta Oncol; 2018 Aug; 57(8):1031-1037. PubMed ID: 29488414
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy.
Franzese C; Comito T; Toska E; Tozzi A; Clerici E; De Rose F; Franceschini D; Navarria P; Reggiori G; Tomatis S; Scorsetti M
Radiother Oncol; 2019 Apr; 133():220-226. PubMed ID: 30414754
[TBL] [Abstract][Full Text] [Related]
10. Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection.
Franzese C; Perrino M; Marzo MA; Badalamenti M; Baldaccini D; D'Agostino G; Marini B; De Vincenzo F; Zucali PA; Scorsetti M
Clin Exp Metastasis; 2022 Jun; 39(3):449-457. PubMed ID: 35190933
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Body Radiotherapy of Lymph Node Oligometastases.
Burkoň P; Oberreiterová S; Kazda T; Slávik M; Bobek L; Komínek L; Procházka T; Vrzal M; Šlampa P
Klin Onkol; 2020; 33(2):114-122. PubMed ID: 32303132
[TBL] [Abstract][Full Text] [Related]
12. Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT).
Habl G; Straube C; Schiller K; Duma MN; Oechsner M; Kessel KA; Eiber M; Schwaiger M; Kübler H; Gschwend JE; Combs SE
BMC Cancer; 2017 May; 17(1):361. PubMed ID: 28532400
[TBL] [Abstract][Full Text] [Related]
13. Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases.
Yeung R; Hamm J; Liu M; Schellenberg D
Radiat Oncol; 2017 Jun; 12(1):105. PubMed ID: 28637480
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study.
Mazzola R; Fersino S; Ferrera G; Targher G; Figlia V; Triggiani L; Pasinetti N; Lo Casto A; Ruggieri R; Magrini SM; Alongi F
Med Oncol; 2018 Aug; 35(9):121. PubMed ID: 30076479
[TBL] [Abstract][Full Text] [Related]
15. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases.
Andratschke N; Alheid H; Allgäuer M; Becker G; Blanck O; Boda-Heggemann J; Brunner T; Duma M; Gerum S; Guckenberger M; Hildebrandt G; Klement RJ; Lewitzki V; Ostheimer C; Papachristofilou A; Petersen C; Schneider T; Semrau R; Wachter S; Habermehl D
BMC Cancer; 2018 Mar; 18(1):283. PubMed ID: 29534687
[TBL] [Abstract][Full Text] [Related]
16. Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes.
Jereczek-Fossa BA; Fanetti G; Fodor C; Ciardo D; Santoro L; Francia CM; Muto M; Surgo A; Zerini D; Marvaso G; Timon G; Romanelli P; Rondi E; Comi S; Cattani F; Golino F; Mazza S; Matei DV; Ferro M; Musi G; Nolè F; de Cobelli O; Ost P; Orecchia R
Clin Genitourin Cancer; 2017 Aug; 15(4):e623-e632. PubMed ID: 28185875
[TBL] [Abstract][Full Text] [Related]
17. Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis.
Nicosia L; Franzese C; Mazzola R; Franceschini D; Rigo M; D'agostino G; Corradini S; Alongi F; Scorsetti M
Strahlenther Onkol; 2020 Mar; 196(3):213-221. PubMed ID: 31559480
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy for pulmonary oligometastases: a monoinstitutional analysis of clinical outcomes and potential prognostic factors.
Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Nicosia L; Ricchetti F; Rigo M; Attinà G; Vitale C; Pastorello E; Ruggieri R; Alongi F
Strahlenther Onkol; 2022 Oct; 198(10):934-939. PubMed ID: 35499694
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases.
Bignardi M; Navarria P; Mancosu P; Cozzi L; Fogliata A; Tozzi A; Castiglioni S; Carnaghi C; Tronconi MC; Santoro A; Scorsetti M
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):831-8. PubMed ID: 20800375
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer.
Franzese C; Zucali PA; Di Brina L; D'Agostino G; Navarria P; Franceschini D; Santoro A; Scorsetti M
Cancer Med; 2018 Sep; 7(9):4379-4386. PubMed ID: 30073758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
